SCHEMBL3273582

SCHEMBL3273582

O=C(/C=C/c1ccc2ccccc2c1)Nc1cc(Cl)ccc1C(=O)NS(=O)(=O)c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 5/20 0.53
FLT4 P35916 5/20 0.53
KDR P35968 5/20 0.53
EGFR P00533 2/20 0.47
TRPA1 O75762 1/20 0.46
KCNK2 O95069 1/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
ALDH1A1 P00352 2/20 0.44
HPGD P15428 2/20 0.44
HCAR2 Q8TDS4 1/20 0.44
POLB P06746 1/20 0.44
MAPT P10636 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
GRIK1 P39086 1/20 0.43
GRIK2 Q13002 1/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
CYP1A2 P05177 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3273588 1.00 FLT1 (0.53) FLT1FLT4KDREGFRTRPA1
SCHEMBL3273574 0.88 EGFR (0.46) EGFRTRPA1KCNK2MEN1KMT2A
SCHEMBL3273565 0.88 EGFR (0.46) EGFRTRPA1KCNK2MEN1KMT2A
SCHEMBL3278122 0.85 EGFR (0.52) EGFRTRPA1MEN1KMT2AALDH1A1
SCHEMBL3278130 0.85 EGFR (0.52) EGFRTRPA1MEN1KMT2AALDH1A1
SCHEMBL3274042 0.84 TRPA1 (0.64) EGFRTRPA1KCNK2MEN1KMT2A
SCHEMBL3274049 0.84 TRPA1 (0.64) EGFRTRPA1KCNK2MEN1KMT2A
SCHEMBL3273494 0.81 EGFR (0.46) EGFRTRPA1KCNK2MEN1KMT2A
SCHEMBL3273489 0.81 EGFR (0.46) EGFRTRPA1KCNK2MEN1KMT2A
SCHEMBL3280717 0.78 EGFR (0.50) EGFRTRPA1MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100087496-A1 NOVEL CINNAMIC AMIDE DERIVATIVES USEFUL AS ION CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2010-04-08 US claimed
US-20100087496-A1 NOVEL CINNAMIC AMIDE DERIVATIVES USEFUL AS ION CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2010-04-08 US disclosed
EP-2121569-A2 NOVEL CINNAMIC AMIDE DERIVATIVES USEFUL AS ION CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2009-11-25 EP disclosed
WO-2008074755-A2 NOVEL CINNAMIC AMIDE DERIVATIVES USEFUL AS ION CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087496-A1 NOVEL CINNAMIC AMIDE DERIVATIVES USEFUL AS ION CHANNEL MODULATORS TRPV1, TRPA1, TRPM8 FLT1 4171/4885FLT4 3811/4885KDR 2970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.